Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aimed at Hard-to-Treat GVHD enters early human testing

NCT ID NCT07138196

Disease control Sponsor: Qurient Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an oral drug called Q702 in 18 people with chronic graft-versus-host disease (cGVHD) that has not responded to standard treatments. The main goals are to check safety, find the right dose, and see early signs of effectiveness. All participants have moderate or severe cGVHD after a stem cell transplant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Adrixetinib (Q702), an oral drug
What this could lead to
If it works, this could point toward a new treatment option for people with chronic GVHD that hasn't responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 18 participants, focused mainly on safety and dosing. It may not show clear benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects who are allogeneic HSCT recipients with moderate or severe active cGVHD requiring systemic immune suppression. 2. Subjects with relapsed or refractory active cGVHD who have progressed after all available standard of care treatments. 3. Subject must have documented progressive disease as defined by the NIH 2014 consensus criteria, in terms of either organ specific algorithm or global assessment, or active, symptomatic cGVHD for which the treating physician believes that a new line of systemic therapy is required. 4. Adequate organ and bone marrow functions. 5. Karnofsky Performance Scale of ≥ 60. Exclusion Criteria: 1. Exposure to CSF1R inhibitor therapy for any indication after allogeneic transplant. 2. Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer. 3. Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years of enrollment. 4. Female subject who is pregnant or breastfeeding. 5. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic graft versus host disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bronchiolitis Obliterans Syndrome chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic graft versus host disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinica Universidad de Navarra

    RECRUITING

    Pamplona, Spain

  • Hospital Clinic de Barcelona

    RECRUITING

    Barcelona, Spain

  • Hospital General Universitario Gregorio Maranon

    RECRUITING

    Madrid, Spain

  • Hospital Universitario Marques de Valdecilla

    RECRUITING

    Santander, Spain

  • Hospital Universitario Puerta de Hierro Majadahonda

    RECRUITING

    Majadahonda, Spain

  • Hospital Universitario Virgen de la Arrixaca

    RECRUITING

    Murcia, Spain

  • Hospital Universitario Virgen del Rocio

    RECRUITING

    Seville, Spain

  • Instituto de Investigacion Sanitaria

    RECRUITING

    Valencia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.